Health professionals’ evaluation of delivering treatment-focused genetic testing to women newly diagnosed with breast cancer
Tóm tắt
Increasingly, women are offered genetic testing shortly after diagnosis of breast cancer to facilitate decision-making about treatment, often referred to as ‘treatment-focused genetic testing’ (TFGT). As understanding the attitudes of health professionals is likely to inform its integration into clinical care we surveyed professionals who participated in our TFGT randomized control study. Thirty-six completed surveys were received (response rate 59 %), 15 (42 %) health professionals classified as genetic and 21 (58 %) as non-genetic. Mainly positive experiences with participating in the TFGT trial were reported. The high cost of testing and who could best deliver information about TGFT to the patient were raised as key constraints to implementation of TFGT in usual care. More non-genetic than genetic health professionals (44 vs 8 %) preferred that the surgeon provide the information for decision-making about TFGT. While costs of TFGT itself and the time and effort of staff involved were perceived barriers, as testing costs become lower, it is expected that TFGT will become a routine part of standard clinical care for patients at high genetic risk in the near future.
Tài liệu tham khảo
Ardern-Jones A, Kenen R, Eeles R (2005) Too much, too soon? Patients and health professionals’ views concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40. Eur J Cancer Care (Engl) 14(3):272–281
Van Riel RE, Warlam-Rodenhuis CC, Verhoef S, Rutgers EJ, Ausems MG (2010) BRCA testing of breast cancer patients: medical specialists’ referral patterns, knowledge and attitudes to genetic testing. Eur J Cancer Care (Engl) 19(3):369–376
Schwartz MD, Lerman C, Brogan B, Peshkin BN, Halbert CH, DeMarco T et al (2004) Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol 22(10):1823–1829
Meiser B, Tucker K, Friedlander M, Barlow-Stewart K, Lobb E, Saunders C et al (2008) Genetic counselling and testing for inherited gene mutations in newly diagnosed patients with breast cancer: a review of the existing literature and a proposed research agenda. Breast Cancer Res 10(6):216
Silva E (2008) Genetic counseling and clinical management of newly diagnosed breast cancer patients at genetic risk for BRCA germline mutations: perspective of a surgical oncologist. Fam Cancer 7(1):91–95
Lobb EA, Barlow-Stewart K, Suthers G, Hallowell N (2010) Treatment-focused DNA testing for newly diagnosed breast cancer patients: some implications for clinical practice. Clin Genet 77(4):350–354
Hartmann LC, Sellers TA, Schaid DJ, Frank TS, Soderberg CL, Sitta DL et al (2001) Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 93(21):1633–1637
Wevers MR, Aaronson NK, Verhoef S, Bleiker EM, Hahn DE, Kuenen MA et al (2014) Impact of rapid genetic counselling and testing on the decision to undergo immediate or delayed prophylactic mastectomy in newly diagnosed breast cancer patients: findings from a randomised controlled trial. Br J Cancer 110(4):1081–1087
Meiser B, Gleeson M, Kasparian N, Barlow-Stewart K, Ryan M, Watts K et al (2012) There is no decision to make: experiences and attitudes toward treatment-focused genetic testing among women diagnosed with ovarian cancer. Gynecol Oncol 124(1):153–157
Zilliacus E, Meiser B, Gleeson M, Watts K, Tucker K, Lobb EA et al (2012) Are we being overly cautious? A qualitative inquiry into the experiences and perceptions of treatment-focused germline BRCA genetic testing amongst women recently diagnosed with breast cancer. Support Care Cancer 20(11):2949–2958
Meiser B, Gleeson M, Watts K, Peate M, Zilliacus E, Barlow-Stewart K et al (2012) Getting to the point: what women newly diagnosed with breast cancer want to know about treatment-focused genetic testing. Oncol Nurs Forum 39(2):E101–E111
Escher M, Sappino AP (2000) Primary care physicians’ knowledge and attitudes towards genetic testing for breast-ovarian cancer predisposition. Ann Oncol 11(9):1131–1135
Burcher S, Meiser B, Mitchell G, Saunders C, Rahman B, Tucker K et al (2013) Oncology health professionals’ attitudes toward treatment-focused genetic testing for women newly diagnosed with breast cancer. Personal Med 10(5):431–440
Watts KJ, Meiser B, Mitchell G, Kirk J, Saunders C, Peate M et al (2012) How should we discuss genetic testing with women newly diagnosed with breast cancer? Design and implementation of a randomized controlled trial of two models of delivering education about treatment-focused genetic testing to younger women newly diagnosed with breast cancer. BMC Cancer 12:320
Hondow HL, Fox SB, Mitchell G, Scott RJ, Beshay V, Wong SQ et al (2011) A high-throughput protocol for mutation scanning of the BRCA1 and BRCA2 genes. BMC Cancer 11:265
Gleeson M, Meiser B, Barlow-Stewart K, Trainer AH, Tucker K, Watts KJ et al (2013) Communication and information needs of women diagnosed with ovarian cancer regarding treatment-focused genetic testing. Oncol Nurs Forum 40(3):275–283